RA0341

antibody from Oursmab

Targeting: IL17A CTLA8, IL-17, IL-17A, IL17

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0341

Provider

Oursmab

Product name

Afasevikumab (Biosimilar Reference Antibody) (IL17A)

Antibody type

Monoclonal

Description

Afasevikumab (RG7624, RO5553110) is a fully human monoclonal antibody of the IgG1\kappa isotype. It is a dual inhibitor designed to simultaneously neutralize the activity of both Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F). By binding to these key pro-inflammatory cytokines, Afasevikumab prevents them from initiating the inflammatory cascade associated with various autoimmune and inflammatory disorders. This dual mechanism was hypothesized to offer greater clinical efficacy than targeting IL-17A alone. It was investigated in Phase I clinical trials for the treatment of inflammatory diseases like autoimmune disorders but appears to have been discontinued in development.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.